Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Shanghai City, China Clinical Trials

A listing of Shanghai City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (50) clinical trials

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.

Phase

0.0 miles

Learn More »

A Phase I Study of SCC244

This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration

Phase

0.0 miles

Learn More »

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial.

Phase

0.0 miles

Learn More »

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

16 subjects with 2 dose groups will be enrolled in the study, all of whom received the SHR-1314 without placebo control. There are 8 subjects in each cohort. The dose will be started at 160mg and will be escalated by following dose escalating rules. The primary endpoint is the safety ...

Phase

0.0 miles

Learn More »

A Phase I Clinical Study to Evaluate the Safety Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.

Phase

0.0 miles

Learn More »

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until occurrence of PD, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor. There will be 5 cohorts in the study. Approximately 20 patients will be enrolled ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Safety Tolerability Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with advanced solid tumor or advanced/metastatic colorectal cancer.

Phase

0.05 miles

Learn More »

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Participants with relapsed/refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma can participate if all eligibility criteria are met.Tests required to determine eligibility include disease assessments, a physical exam, Electrocardiograph, CT/MRI , and blood draws.Participants receive chemotherapy prior to the infusion of CD19 CAR+ T cells. After the infusion, participants ...

Phase

0.05 miles

Learn More »

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

This is an open-labeled phase I clinical study on MBS301 in treatment of patients with HER2 positive recurrent or metastatic malignant solid tumors who have progressed despite standard therapy or are intolerant of standard therapy, or for which no standard therapy exists. The study will include a dose escalation period ...

Phase

0.05 miles

Learn More »

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

Primary Objectives To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients with relapsed and refractory POMES Syndrome. Secondary Objectives To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with POMES Syndrome. To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells.

Phase

0.27 miles

Learn More »